| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
674,040,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$17.15 - $26.07 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Avantor is a global manufacturer and distributor that provides products and services to customers in the biopharmaceutical, healthcare, education and government and advanced technologies and applied materials industries. Co.'s portfolio includes: Materials and consumables, such as lab products and supplies, formulated silicone materials, customized excipients, and customized single-use assemblies; equipment and instrumentation, such as filtration systems, virus inactivation systems, and incubators; and services and specialty procurement, such as onsite lab and production, clinical, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
27,500 |
| Total Buy Value |
$0 |
$0 |
$0 |
$573,100 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
27,872 |
27,872 |
60,449 |
143,821 |
| Total Sell Value |
$687,456 |
$687,456 |
$1,380,595 |
$3,696,863 |
| Total People Sold |
3 |
3 |
4 |
5 |
| Total Sell Transactions |
4 |
4 |
6 |
14 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Brophy Gerard |
EVP, Biopharma Production |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
16,281 |
188,665 |
|
- |
|
| Vanderhaegen Frederic |
EVP, Europe |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
16,281 |
253,669 |
|
- |
|
| Miller Justin |
EVP & General Counsel |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,140 |
121,574 |
|
- |
|
| Andres Juan |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
7,236 |
22,187 |
|
- |
|
| Bramwell James |
EVP, Strategic Partners |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
5,427 |
120,641 |
|
- |
|
| Henrichwark Sven |
EVP, APAC Region |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
5,427 |
19,802 |
|
- |
|
| Ohri Devashish |
EVP, IMEA |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
5,427 |
155,888 |
|
- |
|
| Eck Steven W |
SVP & Chief Accounting Officer |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
6,151 |
32,084 |
|
- |
|
| Peacock Jonathan M |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
7,236 |
168,431 |
|
- |
|
| Shaw Christi |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
7,236 |
18,555 |
|
- |
|
| Summe Gregory L |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
7,236 |
14,818 |
|
- |
|
| Murray Mark Christopher |
EVP, Biomaterials & AT |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,140 |
19,598 |
|
- |
|
| Brophy Gerard |
EVP, Biopharma Production |
• – – |
2021-02-24 |
4 |
AS |
$27.93 |
$85,438 |
D/D |
(3,059) |
172,384 |
|
30% |
|
| Eck Steven W |
SVP & Chief Accounting Officer |
• – – |
2021-02-24 |
4 |
D |
$27.94 |
$72,001 |
D/D |
(2,577) |
25,955 |
|
- |
|
| Eck Steven W |
SVP & Chief Accounting Officer |
• – – |
2021-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,550 |
28,532 |
|
- |
|
| Miller Justin |
EVP & General Counsel |
• – – |
2021-02-22 |
4 |
D |
$28.69 |
$38,732 |
D/D |
(1,350) |
113,434 |
|
- |
|
| Brophy Gerard |
EVP, Biopharma Production |
• – – |
2021-02-22 |
4 |
AS |
$28.62 |
$565,789 |
D/D |
(19,769) |
175,443 |
|
29% |
|
| Brophy Gerard |
EVP, Biopharma Production |
• – – |
2021-02-22 |
4 |
OE |
$17.67 |
$349,318 |
D/D |
19,769 |
195,212 |
|
- |
|
| Brophy Gerard |
EVP, Biopharma Production |
• – – |
2021-02-22 |
4 |
D |
$28.69 |
$88,136 |
D/D |
(3,072) |
175,443 |
|
- |
|
| Ohri Devashish |
EVP, IMEA |
• – – |
2021-02-22 |
4 |
D |
$28.69 |
$34,715 |
D/D |
(1,210) |
150,461 |
|
- |
|
| Stubblefield Michael |
President and CEO |
• • – |
2021-02-22 |
4 |
D |
$28.69 |
$290,945 |
D/D |
(10,141) |
1,437,122 |
|
- |
|
| Szlosek Thomas A |
EVP & CFO |
• – – |
2021-02-22 |
4 |
D |
$28.69 |
$85,496 |
D/D |
(2,980) |
256,374 |
|
- |
|
| Eck Steven W |
SVP & Chief Accounting Officer |
• – – |
2021-02-22 |
4 |
D |
$28.69 |
$12,882 |
D/D |
(449) |
19,982 |
|
- |
|
| Wondrasch Michael |
EVP & CIO |
• – – |
2021-02-22 |
4 |
D |
$28.69 |
$34,686 |
D/D |
(1,209) |
140,334 |
|
- |
|
| Bramwell James |
EVP, Strategic Partners |
• – – |
2021-02-22 |
4 |
D |
$28.69 |
$34,887 |
D/D |
(1,216) |
115,214 |
|
- |
|
542 Records found
|
|
Page 13 of 22 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.12 (0.48%) 
